Chimeric Antigen Receptor News and Research

RSS

Researchers identify mechanism of immune suppression in ovarian cancer

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The study, published Oct. 23 in Nature, points toward a promising new immunotherapy approach for ovarian cancer, which is notoriously aggressive and hard to treat.

24 Oct 2024

Researchers discover how ovarian tumors cripple immune cells

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack-;blocking the energy supply T cells depend on.

23 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers.

16 Oct 2024

Innovative immunotherapy harnesses natural killer T cells to combat solid tumors

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

7 Oct 2024

New cell therapy offers effective treatment for patients with T-cell acute lymphoblastic leukemia

A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options.

7 Oct 2024

Outpatient CAR-T therapy shows promise for treating lymphoma patients

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published today in Blood Advances.

30 Sep 2024

Researchers identify a protein that recharges T cells for long-lasting cancer remission

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of combining type 1 and type 2 immunity.

30 Sep 2024

Study reveals positive correlation between type 2 immunity and long-term cancer remission

Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a negative role in cancer immunity – is positively correlated with long-term cancer remission.

26 Sep 2024

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

New insights into stiff-person syndrome, advancing diagnosis and treatment

Research explores the complexities of diagnosing and treating stiff-person syndrome, emphasizing the uncertain role of GAD antibodies and the promise of novel therapies.

5 Sep 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

New project aims to study the combination of two therapies for pediatric brain cancer

Natasha Sheybani, assistant professor of biomedical engineering at the University of Virginia School of Engineering, will collaborate with researchers at Children's National Hospital to study the combination of two therapies for pediatric brain cancer.

19 Aug 2024

New trial explores BAFF CAR T-cell therapy for relapsed myeloma

University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.

14 Aug 2024

EZH2's role in cancer progression and therapy explored

Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

9 Aug 2024

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells.

5 Aug 2024

FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.

2 Aug 2024

Using advanced CRISPR to boost efficiency of CAR-T cell therapies

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for treating acute lymphoblastic leukemia (ALL).

2 Aug 2024

MD Anderson and collaborators initiate space project to explore T cell behavior in microgravity

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station (ISS) to study the effects of prolonged microgravity on cell differentiation, activation, memory and exhaustion.

31 Jul 2024

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

29 Jul 2024